TOP - Daily
Avoiding intermittent high-dose dexamethasone (HD) when administering the vincristine/doxorubicin/dexamethasone (VAD) regimen can reduce the risk for bacterial infection in patients with multiple myeloma (MM), suggest the results of a Japanese study published in the January issue of the International Journal of Hematology.
The US Food and Drug Administration has approved rituximab (Rituxan, Genentech/Biogen Idec) for maintenance treatment for patients with advanced follicular lymphoma (FL) who responded to induction treatment with rituximab plus chemotherapy.
Use of adjuvant chemotherapy may need to be rethought for patients who experience a pathologic complete response (pCR) or with ypT3-4 residual tumor after neoadjuvant chemoradiation (CRT) for rectal cancer, according to a new analysis presented at the 2011 Gastrointestinal Cancers Symposium (Abstract 361).
Although small, the US Food and Drug Administration (FDA) has identified an increased risk for developing anaplastic large cell lymphoma (ALCL) in the scar capsule adjacent to breast implants. Because the risk is small, pharmacists can help assure women that FDA-approved breast implants are safe when used correctly.
Everolimus plus octreotide LAR increases median progression-free survival over octreotide LAR alone in patients with advanced neuroendocrine tumors (NETs), according to the updated results of the RAD001 In Advanced Neuroendocrine Tumors (RADIANT-2) trial presented at the 2011 Gastrointestinal Cancers Symposium (Abstract 159).
Nimotuzumab shows the potential to improve both progression-free survival (PFS) and overall survival (OS) in patients with epidermal growth factor receptor (EGFR)-positive gastric cancer, according to results of a phase 2 randomized trial presented at the Gastrointestinal Cancers Symposium.
By repeating therapy cycles, clivatuzumab tetraxetan labeled with 90Y plus low-dose gemcitabine improve overall survival (OS) over single-cycle therapy in patients with locally advanced or metastatic pancreatic cancer, according to updated data presented at the Gastrointestinal Cancers Symposium. Researchers also found that as the 90Y labeld clivatuzumab tetraxetan dose increased so did median OS.
A unique partnership will offer an opportunity for patients to attain breakthrough cancer pain medication in the retail setting. ProStakan—the manufacturer of Abstral, a fentynal immediate-release transmucosal tablet—has leveraged RelayHealth’s pharmacy network and McKesson Specialty Care Solutions’ experience in administering risk mitigation and management strategies (REMS) programs to make the agent more readily available for patients.
Two-thirds of patients achieved stable disease with sorafenib after resistance to imatinib and sunitinib treatment for gastrointestinal stromal tumors (GIST), according to a phase 2 trial to be presented at the Gastrointestinal Cancers Symposium.
Two-thirds of patients achieved stable disease with sorafenib after resistance to imatinib and sunitinib treatment for gastrointestinal stromal tumors (GIST), according to a phase 2 trial to be presented at the Gastrointestinal Cancers Symposium.